A recent review from our lab on exploring the pivotal role of ATR and ATM kinases in DNA damage and their promising inhibitors that are currently undergoing clinical trials. This cutting-edge research sheds light on the intricate mechanisms underlying DNA damage response and opens doors to potential breakthroughs in cancer therapy.

Introducing a new drug candidate to the market is a complex and time-demanding process that at least costs pharmaceuticals an average of billion dollars and 10-15 years of research and development. Out of the four stages of drug discovery, the critical yet time-consuming process is identifying the hit and valid drug candidate for the target of interest. This process covers at least 5-6 years in the overall phase of drug discovery. Hence, reducing this gap would eventually decrease the time gap in identifying the hit molecules and fast-track the
drug discovery process.
Our previous findings with TTK, a protein kinase that is highly overexpressed in breast cancer, we aim to develop the protein kinase assay to screen our in-house designed small molecule as a TTK inhibitor. The project goals are to i) design and develop the protein expression and purification assay for TTK and ii) develop a protein inhibition assay for screening the small molecules. The project will further be taken up to more proteins to design the assay kit.